Global Breast Cancer Therapeutics Market to Log 8.3% CAGR 2015-2023 Led by North America
Transparency Market Research has recently published a research report that presents a thorough understanding of the trends and dynamics driving the global breast cancer therapeutics market. The research report, titled “Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” uses SWOT analysis to identify the strengths, weaknesses, opportunities, and threats impacting the various market segments in the overall market. Furthermore, the report also uses Porter’s five forces analysis to highlight the threat of substitute products or services, the threat of new entrants, the bargaining power of customers, the bargaining power of suppliers, and the intensity of competitive rivalry. Through its detailed researching methods, the researchers have compiled a study that details the current market situation as well the prospects for this market.
Browse the full Breast Cancer Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023 report at https://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html
According to the research report, the global breast cancer therapeutics market was valued at US$7.1 bn in 2014 and is anticipated to reach US$16.2 bn by 2023, rising at a CAGR of 8.3% from 2015 to 2023. The drugs and therapies designed and developed for treating breast cancer are known as breast cancer therapeutics. These include biological and regular regimens.
The global breast cancer therapeutics market has been segmented on the basis of the type of drug and geography. The types of drugs in the global breast cancer therapeutics market are HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptor. Geographically, this market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.
The research report shows that the HER2 inhibitors segment was the largest segment of the global breast cancer therapeutics market in 2014. It was valued at US$ 4.90 bn in 2014 and is expected to reach US$ 9.25 bn by 2023, registering a CAGR of 6.2% from 2015 to 2023. This segment is further sub-segmented into Herceptin (Trastuzumab), Tykerb (Lapatinib), Perjeta (Pertuzumab), and Kadcyla (Ado-trastuzumab emtansine). The HER2 inhibitors segment is expected to propel the overall breast cancer therapeutics market as HER2 receptor type cancer can be easily diagnosed due to increasing advancements in targeted therapies and companion testing.
In terms of geography, North America held a dominant share in the global breast cancer therapeutics market in 2014. This dominance was attributable to the supportive insurance schemes that cover expensive treatments for cancer patients. Analysts predict that the cancer market in Asia Pacific is also expected to grow due to high incidence of the deadly disease, growing awareness about breast cancer, and initiatives taken by government bodies in Asia Pacific to tackle breast cancer.
Some of the important players in the global breast cancer therapeutics market are GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Novartis International AG, Puma Biotechnology, Teva Pharmaceutical Industries Ltd., and Sanofi S.A. The research report indicates the state of the competitive landscape of the global breast cancer therapeutics market and explains the regulatory framework governing it. Additionally, the research report also provides a fair understanding of the research and development activities, product portfolio, investment outlook, business and marketing strategies, and financial overview of these top players in the coming few years.
The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class
- Global HER2 Inhibitors Market
- Herceptin (Trastuzumab)
- Tykerb (Lapatinib)
- Perjeta (Pertuzumab)
- Kadcyla (Ado-trastuzumab emtansine)
- Global Mitotic Inhibitors Market
- Halaven (Eribulin)
- Taxotere (Docetaxel)
- Ixempra (Ixabepilone)
- Global Anti-metabolites Market
- Gemzar (Gemcitabine)
- Global Aromatase Inhibitors Market
- Femara (Leterozole)
- Aromasin (Exemestane)
- Arimidex (Anastrozole)
- Ibrance (Palbociclib)
- Afinitor (Everolimus)
- Global Hormone Receptor Market
Global Breast Cancer Therapeutics Market, by Geography
- North America
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa (MEA)
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC